Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EPS (Weighted Average and Diluted) (2016 - 2025)

Cardiff Oncology's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.11 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 47.62% year-over-year to -$0.11; the TTM value through Dec 2025 reached -$0.69, up 26.6%, while the annual FY2025 figure was -$0.69, 27.37% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.11 at Cardiff Oncology, up from -$0.17 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.11 in Q4 2025 and bottomed at -$0.26 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.21 (2025), against an average of -$0.21.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 66.67% in 2021 before it crashed 78.57% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.24 in 2021, then rose by 16.67% to -$0.2 in 2022, then dropped by 5.0% to -$0.21 in 2023, then increased by 0.0% to -$0.21 in 2024, then soared by 47.62% to -$0.11 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's EPS (Weighted Average and Diluted) are -$0.11 (Q4 2025), -$0.17 (Q3 2025), and -$0.21 (Q2 2025).